<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ribavirin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00811</strong>&#160; (APRD00081)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both <span class="caps">RNA</span> and <span class="caps">DNA</span> viruses. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00811/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00811/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00811.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00811.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00811.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00811.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00811.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00811">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ribavirin</td><td>German </td><td>INN</td></tr><tr><td>Ribavirina</td><td>Spanish</td><td>INN</td></tr><tr><td>Ribavirine</td><td>French</td><td>INN</td></tr><tr><td>Ribavirinum</td><td>Latin</td><td>INN</td></tr><tr><td>Tribavirin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Copegus</td><td>Roche</td></tr><tr><td>Moderiba</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rebetol</td><td>Schering-Plough</td></tr><tr><td>Rebretron</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ribamide</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ribasphere</td><td>Three Rivers</td></tr><tr><td>Vilona</td><td>Valeant</td></tr><tr><td>Viramid</td><td>Il Sung</td></tr><tr><td>Virazide</td><td>Grossman</td></tr><tr><td>Virazole</td><td>Meda</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Rebetron (Schering-Plough)</td><td>Ribavirin + Interferon alpha</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiviral-agents">Antiviral Agents</a></li>
<li><a href="/mesh/antimetabolites">Antimetabolites</a></li></ul></td></tr><tr><th>CAS number</th><td>36791-04-5</td></tr><tr><th>Weight</th><td>Average: 244.2047<br>Monoisotopic: 244.080769514</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>IWUCXVSUMQZMFG-AFCXAGJDSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Triazole Ribonucleosides and Ribonucleotides</td></tr><tr><th>Alternative parents</th><td>Pentoses; Triazole Carboxamides; Tetrahydrofurans; Oxolanes; Primary Carboxylic Acid Amides; Secondary Alcohols; 1,2-Diols; Primary Alcohols; Ethers; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>pentose monosaccharide; 1,2,4-triazole carboxamide; 1,2,4-triazole carboxylic acid or derivative; monosaccharide; tetrahydrofuran; 1,2,4-triazole; azole; oxolane; primary carboxylic acid amide; carboxamide group; 1,2-diol; secondary alcohol; polyamine; primary alcohol; enolate; carboxylic acid derivative; carboxylic acid; ether; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the triazole ribonucleosides and ribonucleotides. These are nucleoside derivatives containing a ribose derivative which is n-glycosylated to a triazole.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV).</td></tr><tr><th>Pharmacodynamics</th><td>Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease.</td></tr><tr><th>Mechanism of action</th><td>Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral) and can be incorporated into RNA in RNA viral species.. Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.</td></tr><tr><th>Absorption</th><td>Rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averages 64%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Results of <i>in vitro</i> studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions. Ribavirin has two pathways of metabolism: (1) a reversible phosphorylation pathway in nucleated cells; and (2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>9.5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Apparent cl=26 L/h [A single oral dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects include "flu-like" symptoms, such as headache, fatigue, myalgia, and fever. The LD<sub>50</sub> in mice is 2 g/kg orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion).</td></tr><tr><th>Affected organisms</th><td><ul><li>Hepatitis C virus, RSV and other RNA/DNA viruses</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9852</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7742</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7715</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9507</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.964</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9574</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8329</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8426</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6011</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9462</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9442</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9095</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9535</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9845</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9025
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7406
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9876 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9948
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.919
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Schering plough research institute</li>
<li>Three rivers pharmaceuticals llc</li>
<li>Aurobindo pharma ltd</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Valeant pharmaceuticals international</li>
<li>Schering corp</li>
<li>Hoffmann la roche inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prx Pharmaceuticals</li>
<li><a href="http://www.richmondpharmacy.ca">Richmond Pharmacy</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.schering.de">Schering Corp.</a></li>
<li><a href="http://www.schering-plough.ca">Schering-Plough Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.3riverspharma.com">Three Rivers Pharmaceuticals LLC</a></li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li>
<li>Warrick Pharmaceuticals Corp.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Aerosol</td><td>Respiratory (inhalation)</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01048">Abacavir</a></td><td>Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.</td></tr><tr><td><a href="/drugs/DB00943">Zalcitabine</a></td><td>Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00495">Zidovudine</a></td><td>Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>